Eurofarma initiates new digital platform
Published in: November 8, 2016
and updated in: November 4, 2021
Listen to the text
Stop the audio
In addition to being responsive, the portal integrates the company’s operation in Latin America and expands relationship with its diversified public by means of segmented content and information
São Paulo, November 2016 – The new Eurofarma digital platform (www.eurofarma.com.br) incorporates the user experience (UX) concept while placing the navigation experience of its diversified public as the core of communications and online relationship strategy. With that, the content was conceived in a segmented way, in specific channels to the different users, like physicians, consumers, vets, pharmacists, health professionals, suppliers, and other.
Created and developed by TV1.Com, the portal unifies and integrates the company’s operations in Latin America, present in 15 countries, from pages in Portuguese, English and Spanish, also with the challenge of meeting local norms and specificities by regulatory agencies. The portal is also responsive – adapts to any device, desktop, smartphone or tablet – and counts on a more modern layout.
“The new site gathers technological renovation, Eurofarma idealization and digital trends. Grounded on concepts that are benchmarks in technology like navigability, the portal is intended to be a relationship and content channel, with more attractive visual identity, joining our international operations”, says Maria del Pilar Muñoz, Eurofarma executive director of Sustainability and New Business.
Among the portal’s novelties, is the efficient searcher, which allows the finding of medications per brand, active principle or therapeutic class, with more access liability and wide convergence with the company’s social networks, which facilitates integration and disclosing of different contents. The portal includes sections like Health Dictionary, Article and Myths and Truths.
“To improve the brand visibility on the web and expand traffic and access to the platform, it was developed from Search Engine Optimization (SEO) strategies, adding relevance to the content created by Eurofarma and directs searches on the internet in an organic and natural manner”, explains Mauricio Moreira, planning director at TV1.Com, Grupo TV1 digital market agency (www.grupotv1.com.br).
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br
São Paulo, November 2016 – The new Eurofarma digital platform (www.eurofarma.com.br) incorporates the user experience (UX) concept while placing the navigation experience of its diversified public as the core of communications and online relationship strategy. With that, the content was conceived in a segmented way, in specific channels to the different users, like physicians, consumers, vets, pharmacists, health professionals, suppliers, and other.
Created and developed by TV1.Com, the portal unifies and integrates the company’s operations in Latin America, present in 15 countries, from pages in Portuguese, English and Spanish, also with the challenge of meeting local norms and specificities by regulatory agencies. The portal is also responsive – adapts to any device, desktop, smartphone or tablet – and counts on a more modern layout.
“The new site gathers technological renovation, Eurofarma idealization and digital trends. Grounded on concepts that are benchmarks in technology like navigability, the portal is intended to be a relationship and content channel, with more attractive visual identity, joining our international operations”, says Maria del Pilar Muñoz, Eurofarma executive director of Sustainability and New Business.
Among the portal’s novelties, is the efficient searcher, which allows the finding of medications per brand, active principle or therapeutic class, with more access liability and wide convergence with the company’s social networks, which facilitates integration and disclosing of different contents. The portal includes sections like Health Dictionary, Article and Myths and Truths.
“To improve the brand visibility on the web and expand traffic and access to the platform, it was developed from Search Engine Optimization (SEO) strategies, adding relevance to the content created by Eurofarma and directs searches on the internet in an organic and natural manner”, explains Mauricio Moreira, planning director at TV1.Com, Grupo TV1 digital market agency (www.grupotv1.com.br).
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br